Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
Meropenem Trihydrate
AS Kalceks
J01DH02
Meropenem Trihydrate
Powder for solution for injection/infusion
meropenem
Not marketed
2023-01-20
PACKAGE LEAFLET: INFORMATION FOR THE USER MEROPENEM 500 MG POWDER FOR SOLUTION FOR INJECTION/INFUSION MEROPENEM 1 G POWDER FOR SOLUTION FOR INJECTION/INFUSION meropenem READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. − Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or nurse. − This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. − If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Meropenem is and what it is used for 2. What you need to know before you use Meropenem 3. How to use Meropenem 4. Possible side effects 5. How to store Meropenem 6. Contents of the pack and other information 1. WHAT MEROPENEM IS AND WHAT IT IS USED FOR Meropenem contains the active substance meropenem. It belongs to a group of medicines called carbapenem antibiotics. It works by killing bacteria, which can cause serious infections. This medicine is used to treat the following in adults and children aged 3 months and older: infection affecting the lungs (pneumonia); lung and bronchial infections in patients suffering from cystic fibrosis; complicated urinary tract infections; complicated infections in the abdomen; infections that you can catch during or after the delivery; complicated skin and soft tissues infections; acute bacterial infection of the brain (meningitis). This medicine may be used in the management of patients with low levels of white blood cells called neutrophils with fever that is suspected to be due to a bacterial infection. This medicine may be used to treat bacterial infection of the blood which might be associated with a type of infection mentioned above. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE MEROPENEM DO NOT USE MEROPENEM if you are a Lesen Sie das vollständige Dokument
Health Products Regulatory Authority 20 January 2023 CRN00CFV9 Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Meropenem 500 mg powder for solution for injection/infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains meropenem trihydrate equivalent to 500 mg meropenem. Excipient with known effect Each vial contains approximately 45 mg sodium (as sodium carbonate). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for solution for injection/infusion. White to light yellow powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Meropenem is indicated for the treatment of the following infections in adults and children over 3 months of age (see sections 4.4 and 5.1): Severe pneumonia, including hospital and ventilator‑associated pneumonia Bronchopulmonary infections in cystic fibrosis Complicated urinary tract infections Complicated intra‑abdominal infections Intra- and postpartum infections Complicated skin and soft tissue infections Acute bacterial meningitis Meropenem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The tables below provide general recommendations for dosing. The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response. A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections causes by less susceptible bacterial species (such as _Enterobacterales_, _Pseudomon Lesen Sie das vollständige Dokument